TRPV4/IP3R-1-mediated endothelial pyroptosis drives pulmonary microvascular endothelial permeability in
Shasha Liu1, Shuan Dong2,3,4, Lirong Gong1,5,6
1Department of Anesthesiology and Critical Care Medicine, Tianjin Nankai Hospital, Tianjin Medical University, Tianjin, China.
Background:
Sepsis-induced acute lung injury (ALI) is characterized by edema resulting from increased vascular permeability. Transient receptor potential vanilloid 4 (TRPV4) interacts with inositol 1,4,5-trisphosphate receptor type 1 (IP3R-1) through calmodulin-binding domains and regulates vascular permeability. However, the specific mechanisms underlying the roles of TRPV4 and IP3R-1 in endothelial pyroptosis and vascular permeability remain unclear.
Methods:
EMPs were measured in septic patients and controls, and co-cultured with human pulmonary microvascular endothelial cells (HPMECs). LPS-induced ALI was assessed in wild-type or Gsdmd-/- mice with pharmacological modulation of TRPV4, as well as in Trpv4-/- mice. Pyroptosis was detected in IP3R-1-silenced HPMECs treated with LPS and TRPV4 agonist. IP3R-1/GSDMD interaction was confirmed by structural prediction, Co-IP, and immunofluorescence. Intracellular Ca2+ was detected by flow cytometry, and tissue Ca2+ was visualized by in vivo imaging.
Results:
Elevated EMPs in septic patients enhanced endothelial permeability, upregulated TRPV4 and GSDMD-NT generation in HPMECs. TRPV4 promotes HPMECs permeability and pyroptosis in an IP3R-1-dependent manner. TRPV4 inhibition attenuated lung injury and ameliorated pulmonary dysfunction, while Trpv4 knockdown improved survival. Knockdown of IP3R-1 reduced intracellular Ca2+ and mtDNA levels in HPMECs. In vivo imaging revealed attenuated Ca2+ accumulation in Trpv4-/- mice. The interaction between TRPV4/IP3R-1 and GSDMD was Ca2+-dependent.
Conclusions:
TRPV4 disrupts HPMEC integrity via IP3R-1 and triggers GSDMD-mediated pyroptosis through a Ca2+-dependent mechanism, exacerbating LPS-induced ALI.
Related Concept Videos
Acute Inflammation III: Local and Systemic Effects
Acute Inflammation I: Inflammatory Response
Acute Inflammation II: Cellular Phase


